TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Non-invasive Ventilation by Calibrated Leak in the Treatment of Respiratory Acidosis in ICU

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Dioxide carbon arterial pressure \> 60 mmHg~* Blood acidity (pH) \<7.36~Exclusion Criteria:-Patient age under 18~* Pregnant woman~* Cognitive disorder (other than the one induced by hypercapnia)~* Acute intoxication with morphine or benzodiazepines~* Patient already equipped prior to admission with a home NIV or Continuous Positive Airway Pressure (CPAP) device~* All contraindications to NIV already described in the French Consensus Conference on NIV, from 2006.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Homecare ventilator (Type: EXPERIMENTAL): NIV with a dedicated ventilator for homecare, functioning with a turbine and with vented mask (exhalation by a calibrated leak)
- ICU ventilator (Type: ACTIVE_COMPARATOR): NIV with a dedicated ICU ventilator, functioning with non-vented masks and an exhalation valve.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of CGC-11047 in Patients With Metastatic Hormone Refractory Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Metastatic hormone refractory prostate cancer.~* Eastern Cooperative Oncology Group (ECOG) Performance status of 0-1.~* testosterone \<50ng/dL. Patients must continue primary androgen deprivation with an LHRH analogue if they have not undergone orchiectomy.~* Progressive disease after androgen deprivation.~Exclusion Criteria:~* Patients whose clinical condition would make chemotherapy clearly indicated.~* Patients who have received systemic chemotherapy for the treatment of metastatic disease.~* Peripheral neuropathy \> Grade 1~* Prior anti-angiogenic therapy, including thalidomide.~* Patients with inadequate recovery from any prior surgical procedure, or patients having undergone any major surgical procedure or radiation within 4 weeks prior to study entry.~* Patients who have received radiopharmaceuticals (strontium, samarium) within 8 weeks prior to enrollment.~* Patients with known brain metastases or history of brain metastases.~* History of stroke within 6 months of treatment or other significant neurological limitations.~* Patients who have received more than 2 prior investigational treatments.~* Uncontrolled intercurrent illness~* Patients with a history of a myocardial infarction within the prior 6 months or, hospitalizations for decompensated congestive heart failure within the prior 6 months, or history of significant / symptomatic cardiac arrhythmias

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): CGC-11047 IV weekly for 3 weeks followed by one rest week (4weeks=1cycle)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Atlas Predicted DBS Settings in Essential Tremor

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Seleced for DBS of the VIM nucleus at Vanderbilt Medical center Diagnosis of essential tremor~Exclusion Criteria:~Unable to use the patient handheld programmer

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DBS programming, standard of care (Type: ACTIVE_COMPARATOR): DBS settings determined from the standard Neurologist symptomatic response first then change to settings from Atlas
- DBS progamming from Atlas (Type: EXPERIMENTAL): DBS settings determined from the a functional atlas first then change to settings determined by standard of care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Therapeutic Hypothermia After the Return of Spontaneous Circulation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All patient transported by CCEMS with ROSC after a medical Cardiac Arrest to hospitals that can continue ITH~Exclusion Criteria:~* Less than 18~* Cardiac arrest due to trauma or hemorrhage~* Pregnant women~* patients whom are already hypothermic~* transported to a hospital that can not maintain hypothermia for 24 hours

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Induced Hypothermia (Type: EXPERIMENTAL): Induced hypothermia after the return of spontaneous circulation by the application of ice packs to the axilla and groin with cold IV fluids
- Regular Care (Type: NO_INTERVENTION): Treatment of the return of spontaneous circulation under standing paramedic protocol without the addition of induced therapeutic hypothermia

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Antireflux Efficacy of Hiatal Hernia Repairs in Sleeve Gastrectomy Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All obese patients with a BMI between 35-50~* Aged 18-65 and undergoing surgery for a Sleeve Gastrectomy in institution's bariatric surgery department~Exclusion Criteria:~* hiatal hernias greater than 2 cm,~* hiatal repair requiring mesh placement~* prior bariatric surgery or any other counterindication to Sleeve Gastrectomy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Sleeve Gastrectomy group (Type: ACTIVE_COMPARATOR): This group will receive a Sleeve Gastrectomy only, a mainly restrictive procedure which consists in creating a narrow tube-like stomach based on its lesser curvature.
- Sleeve Gastrectomy + Hiatal Hernia repair group (Type: EXPERIMENTAL): This group will receive a Sleeve Gastrectomy combined with hiatal hernia repair. Hiatal Hernia repair consists of a peri-esophageal dissection proximal to the diaphragmatic crura to achieve an intra-abdominal esophageal length of 2-3 cm. The pillars will then be closed anteriorly and posteriorly using nonabsorbable sutures.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: An Investigational Immuno-therapy Study of Ulocuplumab in Combination With Low Dose Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* Newly Diagnosed Acute Myeloid Leukemia (AML)~* Considered inappropriate for intensive remission induction therapy by an investigator~* Not eligible for stem cell transplantation~Exclusion Criteria:~* Acute promyelocytic leukemia~* Current Myelodysplastic syndrome only subjects~* Unstable angina or uncontrolled congestive heart failure~* Any other malignancy, excluding basal or squamous cell carcinoma of the skin, in situ melanoma, cervical carcinoma in situ, localized prostate cancer, or superficial bladder cancer stage 0, from which the subject has not been disease-free for at least 3 years~* Respiratory disease requiring continuous supplemental oxygen~Other protocol defined inclusion/exclusion criteria could apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ulocuplumab + low dose Cytarabine (Type: EXPERIMENTAL): Ulocuplumab + low dose Cytarabine (LDAC) Phase 1 (escalation cohort) - closed for enrollment
- Ulocuplumab Dose A + low dose Cytarabine (Type: EXPERIMENTAL): Ulocuplumab Dose A + low dose Cytarabine Phase 2 (expansion cohort)
- Ulocuplumab Dose B + low dose Cytarabine (Type: EXPERIMENTAL): Ulocuplumab Dose B + low dose Cytarabine Phase 2 (expansion cohort)
- low dose Cytarabine only (Type: OTHER): Low Dose Cytarabine only Phase 2 (expansion cohort)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The HAM Infliximab Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Are able to give informed consent~* Are 16 years or older~* Have 'definite' HAM/TSP according to the criteria of Definite HAM/TSP agreed in Belem 200361~* Have early or progressing disease as defined here:~  * Early HAM/TSP: Patients must have motor disability (minimum of stiffness or weakness) for less than 2 years. (Bladder symptoms if the original and only presenting symptoms as assessed by history are not included)~* Progressing HAM/TSP~* New or worsening motor symptoms in a patient with definite HAM of \> 2 years duration within the last 3 months~Exclusion Criteria:~* Hepatitis B or hepatitis C infection~* HIV infection~* Overt sepsis, abscesses or opportunistic infections~* Active TB (untreated or on treatment)~* Strongyloides stercoralis (untreated)~* Known hypersensitivity to inflixmab, other murine proteins or to any of the excipients~* Malignancy~* Moderate or severe heart failure (NYHA class III/IV)~* Pregnancy or breastfeeding~* Unhealed surgical wounds~* Planned impending surgery - treatment would be withheld for 2-4 weeks prior to major surgery and started/restarted post-operatively if no evidence of infection and wound healing is satisfactory~* Current immunosuppressive or immunomodulatory therapy

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Infliximab (Type: EXPERIMENTAL): Infliximab 3mg/kg infused intravenously at weeks 0, 2 and 8 and then every 8 weeks until and including week 40 of the study

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: A Very Early Standing Study in Elderly Stroke

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ischemic or hemorrhagic stroke~* Age \> 70~* Modified Rankin Scale (MRS) pre stroke : 0 or 1~* Admission in the neuro vascular unit less than 48 hours after the onset of symptoms~* NIHSS Item 6 for lower extremity motor skills: 3 or 4~* Modified Functional Ambulation Classification : 0~* Affiliated to a social security scheme~Exclusion Criteria:~* History of stroke with motor sequencing limiting walking~* Arterial stenosis limiting the sunrise before D4 (identified by Doppler)~* Symptomatic orthostatic hypotension known or present in the acute phase~* Coma~* Patients who will be referred to a structure (UNV or other) outside the department~* Fracture, orthopedic disorder or any other complication preventing verticalization~* Refusal of the patient to participate in the study or to be verticalized~* Patients under guardianship~* Patients deprived of their liberty by an administrative decision

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Verticalization (Type: EXPERIMENTAL): the patient will be placed in the most vertical position possible.
- Passive mobilization (Type: NO_INTERVENTION): Passive mobilization of the lower limb deficit

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of Sucrose to Reduce Pain in Sick Babies

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Infants who are inpatients of the NICU:~* Who are receiving a continuous intravenous infusion of an opioid analgesic such as morphine or fentanyl at a maximum dose equivalent to 20 mcg/kg/hr of morphine and;~* Who require heel lance for medically required blood sampling or nasogastric/orogastric (NG/OG) tube insertions and;~* Who are eligible to receive sucrose as per the hospital's Sucrose policy for infants.~Exclusion Criteria:~* Infants less than 25 weeks gestation~* Infants with any injury to the skin where the probe needs to be placed~* Infants with an implanted defibrillator or pacemaker~* Infants with an injury affecting sympathetic nerve conduction~* Infants exposed to antenatal methadone~* Infants who, aside from being on opioid analgesics, are ineligible to receive sucrose as per the hospital's Sucrose policy38~* If the infant's mother wishes to breastfeed during the procedure~* Infants with known or suspected fructose intolerance~* Infants with spinal cord malformation (e.g. myelomeningocele and sacral teratoma) since these infant's response, and sensitivity to pain may differ from infants without spinal cord malformations~* Infants who are unconscious, heavily sedated and those with absent gag and/or swallow reflex~* Infants who are in isolation with only essential personnel caring for them~* To ensure there is no interaction effect of muscle relaxants, which may impact on infants' ability to mount a behavioural response to pain, assessments will not be conducted until a period of 24 hours since the previous muscle relaxant dose~* Parental language barrier (if unable to speak/understand French and/or English)

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Sucrose 24% po (Type: EXPERIMENTAL): 24% sucrose solution. The Children's Hospital of Eastern Ontario (CHOE) pharmacy department will provide syringes labeled NICU Pain Relief Study containing a maximum dose of 1 mL of a 24% sucrose solution
- Placebo po (Type: PLACEBO_COMPARATOR): The CHEO pharmacy department will provide a syringe labeled NICU Pain Relief Study containing a maximum of 1 ml dose of water (contents almost identical in color, consistency and odor to the sucrose solution) in identical packagings

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Bilateral Pallidal Stimulation in Patients With Advanced Parkinson's Disease-LATESTIM

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Parkinson's disease according to the UKBB criteria, with the exception that familial forms of otherwise typical parkinsonian syndromes may also be included~* motor complications of dopaminergic medication (dyskinesia or motor fluctuations or both) that are at least moderately bothersome to the patient \[on a scale of 5 possible levels: not at all / mildly / moderately / severely / extremely bothersome\]~* Presence of at least one of the following absolute exclusion criteria for STN stimulation:~  * Mattis dementia rating scale \<130 points~ * postural instability of \>1 in the item of MDS-UPDRS III \[item #12\] on medication~ * less than 30% improvement of axial score in the acute levodopa challenge test \[axial score =sum of items 3.1, 3.9, 3.10, 3.12, 3.13 of the MDS UPDRS III\]~* or presence of at least two of the following relative exclusion criteria for STN stimulation:~  * age \> 70 years~ * Mattis dementia rating scale \<134 points~ * gait freezing on medication~ * dysarthria of \> 2 in the item of the MDS-UPDRS III \[item #3.1\]~ * less than 50% improvement of axial score in the acute levodopa challenge test \[axial score = sum of items 3.1, 3.9, 3.10, 3.12, 3.13 of the MDS UPDRS III\]~ * Starkstein apathy score of ≥14~* Complete baseline PDQ-39-SI and patient diary available~* written informed consent~Exclusion Criteria:~* Age \> 85 years~* surgical or medical contraindications~* abnormalities on brain MRI that preclude the implantation of electrodes into the GPi~* contraindication for 3T MRI (baseline imaging)~* severe medical illness that is likely to hamper the benefit of DBS~* severe personality disorder that may interfere with optimization of DBS~* dementia according to DSM-V and MMSE \< 20~* ongoing psychosis (except pseudohallucinations)~* ongoing major depression (BDI-II \> 23) or depression of any severity with suicidal ideation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- GPi DBS and best medical treatment (Type: EXPERIMENTAL): None
- Best medical treatment (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Safety, Tolerability, Pharmacokinetics, And Effects On Histamine-Induced Wheal Of PF-05180999 In Healthy Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male subjects between the ages of 18 and 55 years~* No history of clinically-relevant atopic or dermatological disease~* Positive reaction to intradermal injection of histamine~Exclusion Criteria:~* Subjects with screening laboratory test results that deviate from the upper and/or lower limits of the reference or acceptable range. The exception is that all liver function tests must not exceed the upper limit of normal.~* Subjects with evidence of, or history of, hepatic disorder, including acute or chronic hepatitis B or hepatitis C~* Intolerance to intradermal histamine injection.~* Subjects with dark skin (Part B only).

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Arm A1 (Type: EXPERIMENTAL): Part A of study to assess safety, tolerability, and pharmacokinetics of PF-05180999
- Arm A2 (Type: PLACEBO_COMPARATOR): Part A of study to assess safety, tolerability, and pharmacokinetics of PF-05180999 relative to placebo
- Arm B1 (Type: EXPERIMENTAL): Part B of study to assess effects of PF-05180999 on histamine-induced wheal
- Arm B2 (Type: EXPERIMENTAL): Part B of study to assess effects of PF-05180999 on histamine-induced wheal
- Arm B3 (Type: EXPERIMENTAL): Positive control to ensure histamine-induced wheal assay integrity
- Arm B4 (Type: EXPERIMENTAL): Placebo control

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: The Value of Screening for HPR in Patients Undergoing Lower Extremity Arterial Endovascular Interventions

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Peripheral arterial disease~* Planned angioplasty or stenting of superficial femoral artery or popliteal artery.~Exclusion Criteria:~* Patients treated on an emergency basis~* Planned intervention on prior site of open surgical intervention (autogenous or autologous bypass, endarterectomy, or patch angioplasty)~* Planned intervention at site exclusive of superficial femoral artery or popliteal artery~* Planned re-stenting at site of prior stent placement~* Planned re-angioplasty at site of prior angioplasty~* Known inability to tolerate antiplatelet regimen before enrollment~* Patients who plan on receiving follow up care outside the University of Pittsburgh Medical Center~* Current use of prasugrel or ticlopidine~* Current use of oral anticoagulation medication~* Pregnant patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Experimental: screening/treating for HPR (Type: EXPERIMENTAL): Participants randomized to this arm will be screened and treated for HPR. Pharmacogenetics testing for CYP2C19 polymorphisms will be collected, stored, and analyzed at study completion.
- Control: guideline based therapy (Type: NO_INTERVENTION): Participants randomized to this arm will receive usual care without screening for HPR. Pharmacogenetics testing for CYP2C19 polymorphisms will be collected, stored, and analyzed at study completion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues